{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Douglas Adamson, Jane Blazeby, Catharine Porter, Christopher Hurt, Gareth Griffiths, Annmarie Nelson, Bernadette Sewell, Mari Jones, Martina Svobodova, Deborah Fitzsimmons, Lisette Nixon, Jim Fitzgibbon, Stephen Thomas, Anthony Millin, Tom Crosby, John Staffurth & Anthony Byrne.

Douglas Adamson ¹, Jane Blazeby ², Catharine Porter ³, Christopher Hurt ³, Gareth Griffiths ⁴, Annmarie Nelson ⁵, Bernadette Sewell ⁶, Mari Jones ⁶, Martina Svobodova ³, Deborah Fitzsimmons ⁶, Lisette Nixon ³, Jim Fitzgibbon ⁷, Stephen Thomas ⁷, Anthony Millin ⁸, Tom Crosby ⁸, John Staffurth ⁸, Anthony Byrne ^5,8,*

¹ Tayside Cancer Centre, Ninewells Hospital, NHS Tayside, Dundee, UK
² Bristol Centre for Surgical Research, NIHR Bristol and Weston Biomedical Research Centre, Bristol University, Bristol, UK
³ Centre for Trials Research, Cardiff University, Cardiff, UK
⁴ Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
⁵ Marie Curie Research Centre, Division of Population Medicine, Cardiff University, Cardiff, UK
⁶ Swansea Centre for Health Economics, Swansea University, Swansea, UK
⁷ Lay research partners, Centre for Trials Research, Cardiff University, Cardiff, UK
⁸ Velindre University NHS Trust, Cardiff, UK
^* Corresponding author Email: Anthony.Byrne2@wales.nhs.uk

Declared competing interests of authors: Douglas Adamson reports grants from Roche (F. Hoffman-La Roche Ltd, Basel, Switzerland) and Boehringer Ingelheim (Ingelheim am Rhein, Germany) outside the submitted work and has given advice to Roche on the development of multidisciplinary team software but received no financial recompense for this. Jane Blazeby is a member of NIHR Clinical Trials Unit (CTU) Standing Advisory Committee (2015–19). Deborah Fitzsimmons reports grants from NIHR during the conduct of the study (PB-PG-0418-20044, RP-PG-1016-20008, RP-PG-0218-20002, RP-PG-0618-20001) and is a member of the European Organisation for Research and Treatment of Cancer Quality of Life Group (1996 to present). Stephen Thomas has received payment from NIHR Health Technology Assessment (HTA) NETSCC Integrated Community Health and Social Care Committee (A) outside the submitted work, and is a member of the NIHR HTA Prioritisation Committee (May 2018 to July 2020). John Staffurth has received personal fees and non-financial support from Janssen oncology (Janssen-Cilag Limited, High Wycombe, UK), non-financial support from Bayer, AG (Leverkusen, Germany), and personal fees from Astellas Pharma Inc. (Tokyo, Japan), outside the submitted work.